Economic Impact of Preoperative Meloxicam IV Administration in Total Knee Arthroplasty: A Randomized Trial Sub-Study
| Autor: | Stewart W. McCallum, Richard Steinfeld, Alex Freyer, Libby K. Black, Alexander P. Sah, Richard D Berkowitz, Drishti Shah, Katharine Coyle, Wei Du, Randall Mack, Vamshi Ruthwik Anupindi, Erin Coyle, Mitch DeKoven |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
business.industry Total knee arthroplasty Length of Stay Meloxicam Placebo Placebo group Confidence interval law.invention Anesthesiology and Pain Medicine Randomized controlled trial law Anesthesia medicine Humans Pharmacology (medical) Hospital Costs Arthroplasty Replacement Knee business medicine.drug |
| Zdroj: | Journal of Pain & Palliative Care Pharmacotherapy. 35:150-162 |
| ISSN: | 1536-0539 1536-0288 |
| DOI: | 10.1080/15360288.2021.1883789 |
| Popis: | We evaluated the economic impact associated with preoperative meloxicam IV 30 mg vs placebo administration among adult total knee arthroplasty (TKA) recipients enrolled in Phase IIIB NCT03434275 trial. Data on total hospital costs and length of stay (LOS) obtained from the trial were compared between meloxicam IV 30 mg and placebo groups. Patients in the meloxicam IV 30 mg vs placebo group (n = 93 vs 88) incurred an adjusted $2,266 (95% CI: -$1,035, $5,116; p = 0.1689) lower total hospital costs and an adjusted 8.6% (95% confidence interval [CI]: -2.0%, 18.1%; p = 0.1082) shorter LOS. While statistically non-significant, based on 95% CIs, the results from this sub-study may suggest a favorable impact associated with meloxicam IV 30 mg on hospital costs and LOS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|